Ser268

Site Information
PQVRVGGssVDLHRF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 450453

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 46 ) , [32P] bio-synthetic labeling ( 46 ) , immunoprecipitation ( 9 ) , mass spectrometry ( 1 , 3 , 4 , 7 , 8 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ) , mutation of modification site ( 5 , 6 , 9 , 45 , 46 ) , phospho-antibody ( 9 , 45 ) , phosphoamino acid analysis ( 46 ) , phosphopeptide mapping ( 46 ) , western blotting ( 9 , 45 )
Disease tissue studied:	anthrax infection ( 21 ) , breast cancer ( 9 ) , colorectal cancer ( 5 , 6 , 9 , 45 ) , colorectal carcinoma ( 5 , 6 , 9 , 45 ) , melanoma skin cancer ( 42 ) , testicular cancer ( 28 , 30 , 31 , 32 , 34 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 3 , 7 , 13 ) , 'fat, brown' ( 22 ) , 3T3 (fibroblast) ( 45 , 46 ) , A431 (epithelial) ( 9 , 45 ) , brain ( 18 , 22 , 23 ) , COLO-205 (intestinal) ( 5 , 6 , 46 ) , COS (fibroblast) ( 45 ) , ES-J1 (stem) ( 27 , 29 , 35 ) , F9 (testicular) ( 28 , 32 , 34 ) , fibroblast-lung ( 24 , 25 , 26 , 37 , 38 , 39 , 40 , 41 ) , HCT116 (intestinal) ( 9 , 45 , 46 ) , heart ( 14 , 22 ) , Hepa 1-6 (epithelial) ( 43 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 10 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 10 ) , HL-1 (myocyte) ( 10 ) , kidney ( 22 ) , liver ( 1 , 12 , 17 , 22 , 44 ) , liver [leptin (mouse), homozygous knockout] ( 17 ) , lung ( 22 ) , macrophage-peritoneum ( 16 ) , MC3T3-E1 (preosteoblast) ( 4 ) , MDA-MB-231 (breast cell) ( 9 ) , MDCK (epithelial) ( 9 , 45 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 19 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 15 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 15 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 20 ) , MEF (fibroblast) ( 15 , 20 ) , mpkCCD (renal) ( 36 ) , P19 (testicular) ( 30 , 31 ) , pancreas ( 22 ) , PYS-2 (epithelial) ( 33 ) , RAW 264.7 (macrophage) ( 8 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 42 ) , spleen ( 21 , 22 ) , SW48 (intestinal) ( 9 ) , testis ( 22 )

Upstream Regulation
Treatments:	bisindolylmaleimide ( 46 ) , IL-33 ( 8 ) , phorbol_ester ( 46 ) , PTH(1-34) ( 4 ) , refeeding ( 17 ) , staurosporine ( 46 )

Downstream Regulation
Effects of modification on CTNND1:	molecular association, regulation ( 6 )
Effects of modification on biological processes:	cell adhesion, inhibited ( 5 , 6 )

References
1	Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127 27818261 Curated Info
2	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
3	Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36 27681418 Curated Info
4	Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50 26160508 Curated Info
5	Maiden SL, Petrova YI, Gumbiner BM (2016) Microtubules Inhibit E-Cadherin Adhesive Activity by Maintaining Phosphorylated p120-Catenin in a Colon Carcinoma Cell Model. PLoS One 11, e0148574 26845024 Curated Info
6	Shashikanth N, et al. (2015) Allosteric Regulation of E-Cadherin Adhesion. J Biol Chem 290, 21749-61 26175155 Curated Info
7	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
8	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
9	Kourtidis A, et al. (2015) Pro-Tumorigenic Phosphorylation of p120 Catenin in Renal and Breast Cancer. PLoS One 10, e0129964 26067913 Curated Info
10	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
11	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
12	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
13	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
14	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
15	Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3 23429704 Curated Info
16	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
17	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
18	Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29 22645316 Curated Info
19	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
20	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
21	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info
22	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
23	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
24	Guo A (2010) CST Curation Set: 9810; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
25	Guo A (2010) CST Curation Set: 9809; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
26	Guo A (2010) CST Curation Set: 9812; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
27	Zhou J (2010) CST Curation Set: 9664; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
28	Zhou J (2010) CST Curation Set: 9671; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
29	Zhou J (2010) CST Curation Set: 9670; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
30	Zhou J (2010) CST Curation Set: 9685; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
31	Zhou J (2010) CST Curation Set: 9668; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
32	Zhou J (2010) CST Curation Set: 9677; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
33	Zhou J (2010) CST Curation Set: 9669; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
34	Zhou J (2010) CST Curation Set: 9665; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
35	Zhou J (2010) CST Curation Set: 9676; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
36	Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7 20139300 Curated Info
37	Guo A (2010) CST Curation Set: 9035; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
38	Guo A (2010) CST Curation Set: 9027; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
39	Guo A (2010) CST Curation Set: 9030; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
40	Guo A (2010) CST Curation Set: 9028; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
41	Guo A (2009) CST Curation Set: 6405; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
42	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
43	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info
44	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info
45	Xia X, Brooks J, Campos-González R, Reynolds AB (2004) Serine and threonine phospho-specific antibodies to p120-catenin. Hybrid Hybridomics 23, 343-51 15684660 Curated Info
46	Xia X, Mariner DJ, Reynolds AB (2003) Adhesion-associated and PKC-modulated changes in serine/threonine phosphorylation of p120-catenin. Biochemistry 42, 9195-204 12885254 Curated Info